Psychedelics as Therapeutics—Potential and Challenges
JAMA Psychiatry · 01.10.2023 · 80 (10) · 979
DOI: 10.1001/jamapsychiatry.2023.1968 ↗Kurz gefasst
Editorial in der Zeitschrift JAMA Psychiatry, erschienen am 01.10.2023. Verfasst von Nora D Volkow und 2 weiteren Autor:innen. Beteiligte Einrichtung: National Institute on Drug Abuse, Gaithersburg, Maryland. Hauptthemen laut MEDLINE: Hallucinogens, Mental Disorders. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
This Viewpoint discusses the potential promise of the therapeutic use of psychedelics for mental illness and substance use disorders, acknowledging many open research questions and unique challenges with these substances.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- National Institute on Drug Abuse, Gaithersburg, Maryland.
- National Institute of Mental Health, Bethesda, Maryland.
Zitieren
APA
Volkow, N. D., Gordon, J. A., & Wargo, E. M. (2023). Psychedelics as Therapeutics—Potential and Challenges. JAMA Psychiatry, 80(10), 979. https://doi.org/10.1001/jamapsychiatry.2023.1968
Vancouver
Volkow ND, Gordon JA, Wargo EM. Psychedelics as Therapeutics—Potential and Challenges. JAMA Psychiatry. 2023;80(10):979. doi:10.1001/jamapsychiatry.2023.1968
BibTeX
@article{Volkow2023,
author = {Volkow, Nora D and Gordon, Joshua A and Wargo, Eric M},
title = {Psychedelics as Therapeutics—Potential and Challenges},
journal = {JAMA Psychiatry},
year = {2023},
volume = {80},
number = {10},
pages = {979},
doi = {10.1001/jamapsychiatry.2023.1968}
}
EUVIMED